Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Group 1: Core Insights - Portage Biotech Inc. reports confirmatory preclinical efficacy data for PORT-7, a selective adenosine A2B receptor inhibitor, demonstrating superior single-agent activity compared to anti-PD1 antibody in a murine mesothelioma model [1] - The combination of PORT-7 and anti-PD1 showed enhanced efficacy over either agent alone, indicating a favorable immune response with increased immune effector cells and the formation of tertiary lymphoid structures [1] - Portage is preparing to initiate a first-in-human clinical trial for PORT-7, addressing the need for novel treatments in aggressive mesothelioma [1] Group 2: Ongoing Developments - Portage is advancing the dose escalation of PORT-6, a selective A2A adenosine receptor inhibitor, with plans to co-administer it with PORT-7 in the ADPORT-601 trial [2] - This combination aims to achieve complete blockade of adenosine-induced immunosuppression in the tumor microenvironment, enhancing anti-tumor responses and broadening the impact of immunotherapy in solid tumors [2] Group 3: Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on advancing a pipeline of novel biologics to enhance the immune system's ability to combat cancer [3]